Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 5;119(1):296-307.
doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Madan Jagasia  1 , Mukta Arora, Mary E D Flowers, Nelson J Chao, Philip L McCarthy, Corey S Cutler, Alvaro Urbano-Ispizua, Steven Z Pavletic, Michael D Haagenson, Mei-Jie Zhang, Joseph H Antin, Brian J Bolwell, Christopher Bredeson, Jean-Yves Cahn, Mitchell Cairo, Robert Peter Gale, Vikas Gupta, Stephanie J Lee, Mark Litzow, Daniel J Weisdorf, Mary M Horowitz, Theresa Hahn
Affiliations

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Madan Jagasia et al. Blood. .

Abstract

Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen on AGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of AGVHD grades in SD cohorts. (A) Cumulative incidence of AGVHD grades B-D in SD cohort stratified by treatment category. (B) Cumulative incidence of AGVHD grades C-D in SD cohort stratified by treatment category.
Figure 2
Figure 2
Cumulative incidence of AGVHD grades in URD cohorts. (A) Cumulative incidence of AGVHD grades B-D in URD cohort stratified by treatment category. (B) Cumulative incidence of AGVHD grades C-D in URD cohort stratified by treatment category.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91. - PubMed
    1. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95(12):3702–3709. - PubMed
    1. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant. 1995;15(5):663–668. - PubMed
    1. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67(4):397–406. - PubMed
    1. Hägglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant. 1995;16(6):747–753. - PubMed

Publication types

MeSH terms